Drugs / SPH6516
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06266923 | Jan 2022 → Apr 2023 | neoplasm | Shanghai Pharmaceuticals Holding Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPH6516 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06266923 ↗ |
| Route | Oral | “Orally” NCT06266923 ↗ |